Meeting
2015 ASCO Annual Meeting
A phase I trial and pharmacokinetic study of non-pegylated liposome-encapsulated doxorubicin citrate (NPLD) plus carboplatin in patients with recurrent gynecological and primary peritoneal tumors.
Authors
Andres Poveda
Instituto Valenciano de Oncologia, Valencia, Spain
Andres Poveda , Ana Oaknin , Ignacio Romero , Angel Guerrero , Laura Calabuig , Jose Maria Del Campo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
EudraCT: 2012-003173-25
Citation
J Clin Oncol 33, 2015 (suppl; abstr 5544)
DOI
10.1200/jco.2015.33.15_suppl.5544
Abstract #
5544
Poster Bd #
102
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A GINECO phase I study evaluating lenalidomide (Le) combined with pegylated liposomal doxorubicin (PLD) and carboplatin (C) in late (>6 months) recurrent ovarian cancer (LROC) patients (pts).
First Author: Frédéric Selle
Poster
2015 ASCO Annual Meeting
Phase I study of vorinostat combined with isotretinoin and temozolomide in adults with recurrent malignant gliomas.
First Author: Marta Penas-Prado
Poster
2012 ASCO Annual Meeting
Phase I trial of pegylated liposomal doxorubicin and lapatinib in the treatment of metastatic breast cancer (MBC): Final results.
First Author: Mary E. Cianfrocca
Poster
2023 ASCO Annual Meeting
Utilizing Drug Combo to improve the design of phase 1 trials for anticancer drugs.
First Author: Lei Wang